

*P<0.05, statistically significant versus sham at the final visit.
Patients with improved BCVA (%)
0
5
10
15
20
25
30
22.2*
18.4*
12.0
DEX 700 (n=351)
DEX 350 (n=347)
Sham (n=350)

FIG. 1



*P<0.05, statistically significant versus sham at the final visit.
Patients with improved BCVA (%)
0
5
10
15
8.5*
11.0*
4.6
DEX 700 (n=351)
DEX 350 (n=347)
Sham (n=350)

FIG. 2



DEX 700 (n = 351)
DEX 350 (n = 347)
Sham (n = 350)
*P ≤ 0.05 versus sham.
BCVA mean change from baseline
Months
10
8
6
4
2
0
-2
0
3
6
9
12
15
18
21
24
27
30
33
36
39
42

FIG. 3



Mean average decrease
from baseline (µm)
0
-20
-40
-60
-80
-100
-120
-140
-160
-180
-200
DEX 700 (n=351)
DEX 350 (n=347)
Sham (n=350)
-111.6*
-107.9*
-41.9
*P<0.05 versus sham.

FIG. 4



*P<0.05, statistically significant
DEX 700 or 350 versus sham
at the final visit.
Patients with improved BCVA (%)
0
5
10
15
20
25
30
ITT
BSL Pseudophakic
BSL Phakic
22.2*
23.3*
21.9*
18.4*
15.9
19.3*
12.0
10.9
12.4
DEX 700
DEX 350
Sham

FIG. 5

	Patients, n (%)		
	DEX 700 N = 347	DEX 350 N = 343	Sham N = 350
Cataract*	178 (27.6)	164 (18.3)	51 (10.8)
Intraocular pressure increased	107 (12.5)	103 (11.7)	12 (1.8)
Conjunctival hemorrhage	73 (8.5)	89 (10.1)	45 (6.8)
Ocular hypertension	21 (2.5)	17 (1.9)	5 (0.8)
Eye pain	18 (2.1)	24 (2.7)	13 (2.0)
Vitreous detachment	17 (2.0)	23 (2.6)	8 (1.2)
Vitreous floaters	17 (2.0)	9 (1.0)	7 (1.1)
Conjunctival edema	15 (1.8)	17 (1.9)	4 (0.6)
Posterior capsule opacification	13 (1.5)	13 (1.5)	7 (1.1)
Vitreous opacities	11 (1.3)	5 (0.6)	3 (0.5)

FIG. 6

	DEX 700, n (%) (N = 347)	DEX 350, n (%) (N = 343)	Sham, n (%) (N = 350)
Trabeculectomy	1 (0.3%)	1 (0.3%)	0 (0.0%)
Iridectomy	1 (0.3%)	0 (0.0%)	1 (0.3%)
Iridotomy	1 (0.3%)	1 (0.3%)	0 (0.0%)
Trabeculoplasty	1 (0.3%)	1 (0.3%)	0 (0.0%)

FIG. 7